
Sanofi India Limited (SANOFI) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
5.4B
Gross Profit
3.0B
55.12%
Operating Income
1.6B
30.29%
Net Income
1.2B
22.30%
EPS (Diluted)
₹51.89
Balance Sheet Metrics
Total Assets
16.1B
Total Liabilities
7.5B
Shareholders Equity
8.6B
Debt to Equity
0.87
Cash Flow Metrics
Revenue & Profitability Trend
Sanofi India Limited Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 19.9B | 28.2B | 27.3B | 29.2B | 28.7B |
Cost of Goods Sold | 10.0B | 12.6B | 12.4B | 13.6B | 12.5B |
Gross Profit | 9.9B | 15.6B | 14.8B | 15.6B | 16.1B |
Gross Margin % | 49.8% | 55.4% | 54.4% | 53.3% | 56.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.6B | 2.5B | 2.4B | 2.4B | 2.4B |
Other Operating Expenses | 1.2B | 1.6B | 1.7B | 1.5B | 2.2B |
Total Operating Expenses | 2.8B | 4.1B | 4.1B | 3.9B | 4.7B |
Operating Income | 4.5B | 7.7B | 6.7B | 7.0B | 6.3B |
Operating Margin % | 22.8% | 27.3% | 24.4% | 23.8% | 22.1% |
Non-Operating Items | |||||
Interest Income | 132.0M | 475.0M | 589.0M | 631.0M | 780.0M |
Interest Expense | 15.0M | 17.0M | 17.0M | 18.0M | 18.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 4.3B | 8.5B | 8.6B | 12.6B | 6.8B |
Income Tax | 1.2B | 2.4B | 2.4B | 3.1B | 2.0B |
Effective Tax Rate % | 27.3% | 28.7% | 28.2% | 24.9% | 29.5% |
Net Income | 4.1B | 6.0B | 6.2B | 9.4B | 4.8B |
Net Margin % | 20.8% | 21.4% | 22.8% | 32.3% | 16.7% |
Key Metrics | |||||
EBITDA | 5.1B | 8.7B | 7.8B | 8.3B | 8.1B |
EPS (Basic) | ₹179.46 | ₹261.78 | ₹269.47 | ₹410.06 | ₹207.38 |
EPS (Diluted) | ₹179.46 | ₹261.78 | ₹269.47 | ₹410.06 | ₹207.38 |
Basic Shares Outstanding | 23030622 | 23030622 | 23030622 | 23030622 | 23030622 |
Diluted Shares Outstanding | 23030622 | 23030622 | 23030622 | 23030622 | 23030622 |
Income Statement Trend
Sanofi India Limited Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.8B | 3.9B | 10.0B | 15.4B | 12.0B |
Short-term Investments | 562.0M | 198.0M | 190.0M | 123.0M | 281.0M |
Accounts Receivable | 2.3B | 1.3B | 1.3B | 1.4B | 1.5B |
Inventory | 5.0B | 6.6B | 4.1B | 3.9B | 3.7B |
Other Current Assets | 2.0M | 264.0M | 325.0M | 284.0M | 28.0M |
Total Current Assets | 11.3B | 12.5B | 16.1B | 21.4B | 18.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.1B | 3.1B | 589.0M | 604.0M | 593.0M |
Goodwill | 13.0M | 75.0M | 51.0M | 52.0M | 1.8B |
Intangible Assets | 13.0M | 75.0M | 51.0M | 52.0M | 381.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 41.0M | 55.0M | 77.0M | 45.0M | 44.0M |
Total Non-Current Assets | 4.8B | 4.7B | 4.6B | 9.2B | 10.9B |
Total Assets | 16.1B | 17.1B | 20.7B | 30.6B | 29.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.1B | 2.9B | 3.6B | 3.8B | 3.2B |
Short-term Debt | 53.0M | 51.0M | 87.0M | 70.0M | 47.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 48.0M | 96.0M | 129.0M | 94.0M | 77.0M |
Total Current Liabilities | 7.2B | 6.5B | 7.4B | 7.5B | 6.9B |
Non-Current Liabilities | |||||
Long-term Debt | 140.0M | 139.0M | 149.0M | 176.0M | 179.0M |
Deferred Tax Liabilities | 0 | 37.0M | 49.0M | 63.0M | 302.0M |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 320.0M | 483.0M | 553.0M | 858.0M | 1.1B |
Total Liabilities | 7.5B | 7.0B | 8.0B | 8.4B | 8.0B |
Equity | |||||
Common Stock | 230.0M | 230.0M | 230.0M | 230.0M | 230.0M |
Retained Earnings | 4.5B | 6.0B | 8.4B | 18.0B | 16.9B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.6B | 10.2B | 12.8B | 22.3B | 21.2B |
Key Metrics | |||||
Total Debt | 193.0M | 190.0M | 236.0M | 246.0M | 226.0M |
Working Capital | 4.1B | 6.0B | 8.7B | 13.9B | 11.5B |
Balance Sheet Composition
Sanofi India Limited Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 5.6B | 8.5B | 8.6B | 12.6B | 6.8B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 12.0M | 61.0M | 21.0M | 61.0M | 117.0M |
Working Capital Changes | -1.8B | -2.6B | 16.0M | -88.0M | 569.0M |
Operating Cash Flow | 3.7B | 5.5B | 8.1B | 11.9B | 6.7B |
Investing Activities | |||||
Capital Expenditures | -358.0M | -100.0M | 131.0M | 148.0M | -410.0M |
Acquisitions | - | - | 1.3B | 5.5B | 2.4B |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -358.0M | -100.0M | 1.5B | 5.8B | 2.0B |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -3.8B | -8.7B | -15.7B | -8.4B | -8.0B |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -3.8B | -8.7B | -15.7B | -8.4B | -8.0B |
Free Cash Flow | 4.3B | 2.0B | 3.8B | 5.4B | 5.7B |
Net Change in Cash | -524.0M | -3.3B | -6.2B | 9.3B | 646.0M |
Cash Flow Trend
Sanofi India Limited Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
33.00
Forward P/E
25.52
Price to Book
15.31
Price to Sales
6.05
PEG Ratio
25.52
Profitability Ratios
Profit Margin
18.29%
Operating Margin
21.12%
Return on Equity
49.43%
Return on Assets
22.47%
Financial Health
Current Ratio
1.85
Debt to Equity
2.67
Beta
0.08
Per Share Data
EPS (TTM)
₹157.54
Book Value per Share
₹339.62
Revenue per Share
₹860.23
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
sanofi | 119.9B | 33.00 | 15.31 | 49.43% | 18.29% | 2.67 |
GlaxoSmithKline | 455.2B | 47.81 | 23.33 | 47.54% | 25.41% | 0.51 |
Pfizer | 228.5B | 29.77 | 5.42 | 19.65% | 33.65% | 2.57 |
Sanofi Consumer | 119.5B | 59.51 | 46.41 | 66.30% | 27.62% | 11.01 |
Marksans Pharma | 95.6B | 25.12 | 3.88 | 16.73% | 14.51% | 12.93 |
Senores | 30.2B | 44.69 | 3.90 | 7.21% | 14.82% | 38.75 |
Financial data is updated regularly. All figures are in the company's reporting currency.